Published in CMAJ on April 27, 2004
Management of agitation and aggression associated with Alzheimer disease. Nat Rev Neurol (2009) 1.86
Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study. BMJ (2005) 1.84
Metabolic changes associated with second-generation antipsychotic use in Alzheimer's disease patients: the CATIE-AD study. Am J Psychiatry (2009) 1.70
Effect of regulatory warnings on antipsychotic prescription rates among elderly patients with dementia: a population-based time-series analysis. CMAJ (2008) 1.34
Diagnosis and treatment of dementia: 6. Management of severe Alzheimer disease. CMAJ (2008) 1.21
Genetics of psychosis in Alzheimer's disease: a review. J Alzheimers Dis (2010) 1.02
Antipsychotics for the treatment of behavioral and psychological symptoms of dementia (BPSD). Curr Neuropharmacol (2008) 0.95
Increased mortality among elderly patients with dementia using atypical antipsychotics. CMAJ (2005) 0.94
Second-generation antipsychotics in dementia: beyond safety concerns. A clinical, systematic review of efficacy data from randomised controlled trials. Psychopharmacology (Berl) (2010) 0.87
Cardiovascular and cerebrovascular risk factors and events associated with second-generation antipsychotic compared to antidepressant use in a non-elderly adult sample: results from a claims-based inception cohort study. World Psychiatry (2015) 0.86
The explanatory role of stroke as a mediator of the mortality risk difference between older adults who initiate first- versus second-generation antipsychotic drugs. Am J Epidemiol (2014) 0.82
Antipsychotic treatments for the elderly: efficacy and safety of aripiprazole. Neuropsychiatr Dis Treat (2010) 0.79
Olanzapine as a possible treatment of behavioral symptoms in vascular dementia: risks of cerebrovascular events. A controlled, open-label study. J Neurol (2005) 0.78
Safety and efficacy of antipsychotic drugs for the behavioral and psychological symptoms of dementia. Indian J Psychiatry (2009) 0.77
Autonomic nervous system and risk factors for vascular disease. Effects of autonomic unbalance in schizophrenia and Parkinson's disease. Neurol Sci (2008) 0.77
Management of psychosis in patients with Alzheimer's disease: focus on aripiprazole. Clin Interv Aging (2008) 0.76
The effect of federal and state off-label marketing investigations on drug prescribing: The case of olanzapine. PLoS One (2017) 0.75
Arterial Stiffness in Patients Taking Second-generation Antipsychotics. Clin Psychopharmacol Neurosci (2016) 0.75
Use pattern and off-label use of atypical antipsychotics in bipolar disorder, 1998-2002. Am Health Drug Benefits (2009) 0.75
The Ticking of the Epigenetic Clock: Antipsychotic Drugs in Old Age. Front Endocrinol (Lausanne) (2016) 0.75
Profile of atypical-antipsychotics use in patients affected by dementia in the University Hospital of Ferrara. Eur J Clin Pharmacol (2010) 0.75
Electrocardiographic monitoring for new prescriptions of quetiapine co-prescribed with acetylcholinesterase inhibitors or memantine from 2005 to 2009. A population study on community-dwelling older people in Italy. Eur J Clin Pharmacol (2014) 0.75
Can systematic reviews contribute to regulatory decisions? Eur J Clin Pharmacol (2017) 0.75
Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials. CMAJ (2002) 2.41
Choice of an antipsychotic. Med Lett Drugs Ther (2003) 1.42
Tips for learning and teaching evidence-based medicine: introduction to the series. CMAJ (2004) 3.23
Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials. CMAJ (2002) 2.41
Herbal kava: reports of liver toxicity. CMAJ (2002) 2.17
Concerns over lindane treatment for scabies and lice. CMAJ (2003) 2.01
Droperidol: cardiovascular toxicity and deaths. CMAJ (2002) 1.68
Rosiglitazone (Avandia) and pioglitazone (Actos) and heart failure. CMAJ (2002) 1.64
Cochlear implant recipients at risk for meningitis. CMAJ (2002) 1.61
Rosiglitazone (Avandia) and macular edema. CMAJ (2006) 1.50
A catalyst for change. CMAJ (2006) 1.48
Alcohol-associated rapid release of a long-acting opioid. CMAJ (2005) 1.42
Congratulations to our colleagues at Open Medicine. CMAJ (2007) 1.39
Brief safety updates: acetaminophen, ASA and kava. CMAJ (2002) 1.38
New restrictions on celecoxib (Celebrex) use and the withdrawal of valdecoxib (Bextra). CMAJ (2005) 1.29
Too much of a good thing? Toxic effects of vitamin and mineral supplements. CMAJ (2003) 1.27
Propofol: contraindicated for sedation of pediatric intensive care patients. CMAJ (2002) 1.25
Diane-35 (cyproterone acetate): safety concerns. CMAJ (2003) 1.22
What's all the fuss? Safety concerns about COX-2 inhibitors rofecoxib (Vioxx) and celecoxib (Celebrex). CMAJ (2002) 1.18
Paroxetine (Paxil) and congenital malformations. CMAJ (2005) 1.03
Bupropion (Zyban, Wellbutrin SR): reports of deaths, seizures, serum sickness. CMAJ (2002) 0.99
Salmeterol (Serevent) asthma trial halted early. CMAJ (2003) 0.99
Rosuvastatin (Crestor) and rhabdomyolysis. CMAJ (2004) 0.97
Increased mortality among elderly patients with dementia using atypical antipsychotics. CMAJ (2005) 0.94
Eczema drugs tacrolimus (Protopic) and pimecrolimus (Elidel): cancer concerns. CMAJ (2005) 0.93
Tamoxifen for breast cancer prevention: safety warning. CMAJ (2002) 0.92
Obesity drug sibutramine (Meridia): hypertension and cardiac arrhythmias. CMAJ (2002) 0.90
Antipsychotic clozapine (Clozaril): myocarditis and cardiovascular toxicity. CMAJ (2002) 0.90
Facts on mercury and fish consumption. CMAJ (2002) 0.88
Paroxetine (Paxil, Seroxat): increased risk of suicide in pediatric patients. CMAJ (2003) 0.88
Visual loss with erectile dysfunction medications. CMAJ (2006) 0.88
Ephedra/ephedrine: cardiovascular and CNS effects. CMAJ (2002) 0.88
HIV drug stavudine (Zerit, d4T) and symptoms mimicking Guillain-Barré syndrome. CMAJ (2002) 0.87
Noninvasive treatments for umbilical granulomas. Am Fam Physician (2003) 0.85
Long-acting beta2-agonists in asthma: safety concerns. CMAJ (2005) 0.84
Accutane (isotretinoin) and psychiatric adverse effects. CMAJ (2003) 0.83
Suicidal ideation among children taking atomoxetine (Strattera). CMAJ (2005) 0.83
Diabetes drug pioglitazone (Actos): risk of fracture. CMAJ (2007) 0.83
Failure of rapid HIV tests. CMAJ (2002) 0.83
People with diabetes should avoid antibiotic gatifloxacin. CMAJ (2006) 0.82
The Canadian Hypertension Education Program (CHEP) recommendations: launching a new series. CMAJ (2005) 0.82
Striving for excellence: developing a framework for the Triple C curriculum in family medicine education. Can Fam Physician (2012) 0.82
Septic shock after medical abortions with mifepristone (Mifeprex, RU 486) and misoprostol. CMAJ (2005) 0.82
Infliximab and serious hematologic events. CMAJ (2004) 0.80
Medications for attention deficit hyperactivity disorder: cardiovascular concerns. CMAJ (2006) 0.80
Mefloquine: contraindicated in patients with mood, psychotic or seizure disorders. CMAJ (2002) 0.79
Asthma drug zafirlukast (Accolate): serious hepatic events. CMAJ (2004) 0.79
Patients receiving intravenous bisphosphonates should avoid invasive dental procedures. CMAJ (2005) 0.79
Medroxyprogesterone acetate (Depo-Provera) and bone mineral density loss. CMAJ (2005) 0.78
HIV drug nevirapine (Viramune): risk of severe hepatotoxicity. CMAJ (2004) 0.78
Oseltamivir (Tamiflu) unsafe in infants under 1 year old. CMAJ (2004) 0.78
Nephrology in practice: a new series. CMAJ (2002) 0.77
Osteoporosis treatment: raloxifene (Evista) and stroke mortality. CMAJ (2006) 0.76
Tegaserod (Zelnorm) for irritable bowel syndrome: reports of serious diarrhea and intestinal ischemia. CMAJ (2004) 0.76
Nail gun. CMAJ (2002) 0.75
Is the timing of infant cereal introduction a risk factor for celiac disease autoimmunity? CMAJ (2005) 0.75
Serious allergic reactions following tuberculin skin tests. CMAJ (2005) 0.75
Hua Fo tablets tainted with sildenafil-like compound. CMAJ (2002) 0.75
Earlier clinical conundrum resolved: a diagnosis with teeth. CMAJ (2005) 0.75
The Evra (ethinyl estradiol/norelgestromin) contraceptive patch: estrogen exposure concerns. CMAJ (2005) 0.75
Several Chinese herbal products may contain toxic aristolochic acid. CMAJ (2004) 0.75
Medical gels and the risk of serious infection. CMAJ (2004) 0.75
Ototoxic effects from gentamicin ear drops. CMAJ (2002) 0.75
Persistent pulmonary hypertension of the newborn and maternal use of SSRIs. CMAJ (2006) 0.75
WinRho and disseminated intravascular coagulopathy. CMAJ (2006) 0.75
Triptan migraine treatments and antidepressants: risk of serotonin syndrome. CMAJ (2006) 0.75
Combination hormone replacement therapy and dementia. CMAJ (2003) 0.75
Meniscus. CMAJ (2002) 0.75
Patient information about HPV and the HPV vaccine. CMAJ (2007) 0.75
Epoetin alfa (Eprex): reports of pure red blood cell aplasia. CMAJ (2002) 0.75